Search Results - "BALSHAW, R."

Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017 by Skowronski, Danuta M, Chambers, Catharine, Sabaiduc, Suzana, Dickinson, James A, Winter, Anne-Luise, De Serres, Gaston, Drews, Steven J, Jassem, Agatha, Gubbay, Jonathan B, Charest, Hugues, Balshaw, Robert, Bastien, Nathalie, Li, Yan, Krajden, Mel

“…Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network (SPSN) assessed interim 2016/17 influenza vaccine effectiveness (VE)…”
Get full text

Differential Proteomics for Distinguishing Ischemic Stroke from Controls: a Pilot Study of the SpecTRA Project by Penn, A. M., Saly, V., Trivedi, A., Lesperance, M. L., Votova, K., Jackson, A. M., Croteau, N.S., Balshaw, R. F., Bibok, M. B., Smith, D. S., Lam, K. K., Morrison, J., Lu, L., Coutts, S. B., Borchers, C. H.

“…A diagnostic blood test for stroke is desirable but will likely require multiple proteins rather than a single “troponin.” Validating large protein panels…”
Get full text

Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy by Sherman, M, Yoshida, E M, Deschenes, M, Krajden, M, Bain, V G, Peltekian, K, Anderson, F, Kaita, K, Simonyi, S, Balshaw, R, Lee, S S

“…Background: The management of patients with chronic hepatitis C who have relapsed or failed to respond to interferon based therapies is an important issue…”
Get full text

Predictive Ability of Pretransplant Comorbidities to Predict Long‐Term Graft Loss and Death by Machnicki, G., Pinsky, B., Takemoto, S., Balshaw, R., Salvalaggio, P. R., Buchanan, P. M., Irish, W., Bunnapradist, S., Lentine, K. L., Burroughs, T. E., Brennan, D. C., Schnitzler, M. A.

“…Whether to include additional comorbidities beyond diabetes in future kidney allocation schemes is controversial. We investigated the predictive ability of…”
Get full text

Biomarkers Monitoring for Absence of Acute Allograft Rejection by Hollander, Z, Dai, D.L, Shannon, C, Chen, V, Lam, K.K, McManus, J.E, Assadian, S, Toma, M, Tebbutt, S.J, Balshaw, R, Borchers, C.H, Davies, R.A, Delgado, D, Haddad, H, Ignaszewski, A, Isaac, D.L, Kim, D, Mui, A, Rajda, M, Ross, H, West, L.J, White, M, Zieroth, S, McMaster, W, Keown, P.A, Ng, R.T, McManus, B.M

Get full text

Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3 by Lee, S. S., Sherman, M., Ramji, A., Greenbloom, S., Elkashab, M., Pluta, H., Hilzenrat, N., Balshaw, R., Usaty, C., Myers, R. P.

“…Aliment Pharmacol Ther 2012; 35: 37–47 Summary Background  The efficacy of individualised antiviral treatment durations for chronic hepatitis C remains…”
Get full text

Interferon-gamma release assays are a better tuberculosis screening test for hemodialysis patients: A study and review of the literature by Grant, J, Jastrzebski, J, Johnston, J, Stefanovic, A, Jastrabesky, J, Elwood, K, Roscoe, D, Balshaw, R, Bryce, E

“…Diagnosing latent tuberculosis (TB) infection (LTBI) in dialysis patients is complicated by poor response to tuberculin skin testing (TST), but the role of…”
Get full text

Association between dinucleotide repeat in non-coding region of interferon-gamma gene and susceptibility to, and severity of, rheumatoid arthritis by Khani-Hanjani, A, Lacaille, D, Hoar, D, Chalmers, A, Horsman, D, Anderson, M, Balshaw, R, Keown, PA

“…Rheumatoid arthritis ranges from a mild, nondeforming arthropathy with little long-term disability to severe, incapacitating, deforming arthritis which may be…”
Get full text

Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa‐2a plus ribavirin by BAIN, V. G., LEE, S. S., PELTEKIAN, K., YOSHIDA, E. M., DESCHÊNES, M., SHERMAN, M., BAILEY, R., WITT‐SULLIVAN, H., BALSHAW, R., KRAJDEN, M.

“…Summary Background  The impact of reduced drug exposure on outcomes in patients with chronic hepatitis C has not been determined in routine clinical practice…”
Get full text

Inadequate pain relief (IPR) in knee osteoarthritis: what does it look like? a European survey of osteoarthritis real world therapies (SORT) by Conaghan, P, Rannou, F, Arden, N, Everett, S.V, Balshaw, R, Peloso, P.M, Watson, D.J, Sen, S.S, Taylor, S.D

Get full text

250 The Likelihood of Acute Cardiac Rejection Can Be Predicted at Transplantation by Hollander, Z, Chen, V, Ng, R.T, Balshaw, R, Wilson-McManus, J.E, Ignaszewski, A, McMaster, R.W, Keown, P.A, McManus, B.M

Get full text

Blood Test to Monitor for the Absence of Acute Cardiac Rejection: From Discovery to Clinical Implementation by Hollander, Z, Lam, K.K, Wilson-McManus, J.E, Assadian, S, Dai, D.L, Shannon, C, Chen, V, Tebbutt, S.J, Balshaw, R, Borchers, C, Davies, R.A, Delgado, D, Haddad, H, Ignaszewski, A, Isaac, D.L, Kim, D.H, Mui, A, Rajda, M, Ross, H, West, L.J, White, M, Zieroth, S, McMaster, R.W, Keown, P.A, Ng, R.T, McManus, B.M

Get full text

Plasma Protein Biosignatures for Detection of Cardiac Allograft Vasculopathy by Toma, M, Hollander, Z, Wilson-McManus, J.E, Lin, D, Lam, K.K, Dai, D.L, Cohen Freue, G, Tebbutt, S.J, Balshaw, R, Borchers, C, Davies, R.A, Delgado, D, Haddad, H, Ignaszewski, A, Isaac, D.L, Kim, D.H, Rajda, M, Ross, H, West, L.J, White, M, Zieroth, S, Mancini, J.G, McMaster, R.W, Keown, P.A, Ng, R.T, McManus, B.M

Get full text

Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3 by Powis, J., Peltekian, K. M., Lee, S. S., Sherman, M., Bain, V. G., Cooper, C., Krajden, M., Deschenes, M., Balshaw, R. F., Heathcote, E. Jenny, Yoshida, E. M.

“…Chronic hepatitis C virus (HCV) infections with genotype 2 or 3 are associated with favourable sustained virologic response (SVR) rates. However, genotype 3…”
Get full text

The use of consensus guidelines for management of cytomegalovirus infection in renal transplantation by Dmitrienko, S., Yu, A., Balshaw, R., Shapiro, R.J., Keown, P.A.

“…Cytomegalovirus (CMV) infection imposes a significant economic burden on susceptible patients after renal transplantation. Our study was conducted to determine…”
Get full text

193 Biomarkers of Recovered Heart Function by Hollander, Z, Lazárová, M, Ignaszewski, A, Chen, V, Ng, R.T, Wilson-McManus, J.E, Balshaw, R, McMaster, R.W, Keown, P.A, McManus, B.M

Get full text

427 Health Economic Evaluation of Predictive and Diagnostic Biomarkers of Acute Cardiac Rejection by Hollander, Z, Mohammadi, T.H.G, Co, M, Wilson-McManus, J.E, Ng, R.T, Balshaw, R, McMaster, R.W, Keown, P.A, McManus, B.M, Marra, C

Get full text

Biomarkers in transplantation: Prospective, blinded measurement of predictive value for the flow cytometry crossmatch after negative antiglobulin crossmatch in kidney transplantation by Wen, R., Wu, V., Dmitrienko, S., Yu, A., Balshaw, R., Keown, P.A.

“…This prospective, blinded observational study was conducted to measure the predictive value the of flow cytometric crossmatch for biopsy-proven acute…”
Get full text

PMS59 Inadequate Pain Relief in Knee Osteoarthritis and Patient Reported outcomes: A Survey of Osteoarthritis Real World Therapies (SORT) in the United Kingdom by Jameson, K, Balshaw, R, Phillips, C, Martin, G.R, Everett, S.V, Watson, D.J, Taylor, S.D

Get full text

Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia by Williams, R., Kopala, L., Malla, A., Smith, G., Love, L., Balshaw, R.

“…Objective:  To evaluate over a 2‐year period, patients from academic/non‐academic centres, from each region of Canada, to determine whether location or other…”
Get full text